|
Defactinib Clinical Trials
10 actively recruiting trials across 6 locations
Also known as: PF-04554878, VS-6063, defactinib (VS-6063)
Pipeline
Phase 1: 1Phase 2: 6Phase 3: 1Phase 1/2: 2
Top Sponsors
- Memorial Sloan Kettering Cancer Center3
- Verastem, Inc.1
- University of Utah1
- Ryan H. Moy, MD, PhD1
- M.D. Anderson Cancer Center1
Indications
- Cancer10
- Low-Grade Serous Ovarian Cancer2
- Glioblastoma Multiform (Grade IV Astrocytoma)1
- Malignant Primary Gliomas1
- Diffuse Hemispheric Glioma, H3 G34-mutant1
Other2 trials
Atlanta, Georgia2 trials
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Emory Winship Cancer Institute
Phase 2
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University Hospital Midtown
Phase 2
Basking Ridge, New Jersey2 trials
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 2
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 2
Phoenix, Arizona1 trial
Iowa City, Iowa1 trial
New York, New York1 trial
Avutometinib and Defactinib in Diffuse Gastric Cancer
Columbia University Irving Medical Center
Phase 2
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.